CRPC

Thimble Island Private Wealth Launches With Support From LPL Strategic Wealth Services

Retrieved on: 
Dienstag, Mai 7, 2024
CRPC, LPL Financial, CFO, SW, Business development, Entrepreneurship, Penn Mutual, Freedom, Culture, SAN, LPL, Financial adviser

SAN DIEGO, May 07, 2024 (GLOBE NEWSWIRE) -- LPL Financial LLC announced today that financial advisors Logan Reed, CFP®, CEPA®, CIMA®, CLU®, AIF®, James “Jim” English III, Michael Allegra Jr., CRPC, and Matthew Fleming, CFP®, have launched a new independent practice, Thimble Island Private Wealth, through affiliation with LPL Financial’s supported independence model, LPL Strategic Wealth Services .

Key Points: 
  • SAN DIEGO, May 07, 2024 (GLOBE NEWSWIRE) -- LPL Financial LLC announced today that financial advisors Logan Reed, CFP®, CEPA®, CIMA®, CLU®, AIF®, James “Jim” English III, Michael Allegra Jr., CRPC, and Matthew Fleming, CFP®, have launched a new independent practice, Thimble Island Private Wealth, through affiliation with LPL Financial’s supported independence model, LPL Strategic Wealth Services .
  • Based in New Haven, Conn., the quartet of experienced advisors share a commitment to providing personalized, concierge-level service to their clients.
  • The 2024 Forbes Best-In-State Wealth Management Team takes a collective approach to help ensure that each client receives hands-on attention for their unique financial needs.
  • We look forward to supporting Thimble Island Private Wealth for years to come.”

Tellbio’s Technology Demonstrates that Analysis of Circulating Tumor Cells Can Predict Survival Among Patients with Metastatic Castration-Resistant Prostate Cancer Receiving Radium-2230

Retrieved on: 
Mittwoch, März 27, 2024
OS, Harvard Medical School, DOI, Radium-223, Prostate cancer, Gene expression, Metastasis, Doctor of Pharmacy, JCO, Assistant, Patient, Tap, Biomarker, RNA, Chinese, Quality of life, CRPC, Senior, Hospital, Prognosis, CTC, Radiation therapy, PSA, FDA, CTCM, Medical imaging

ANDOVER, Mass., March 27, 2024 (GLOBE NEWSWIRE) -- TellBio, Inc., a development-stage medical technology company focused on revolutionizing the detection of cancer metastasis through its unique and proprietary circulating tumor cell (CTC) technology, the TellDx CTC System, announces the publication of data that shows the promise of CTCs as a prognostic biomarker for patients with prostate cancer receiving novel therapies such as radium-223. The paper, “Circulating and Imaging Biomarkers of Radium-223 Response in Metastatic Castration-Resistant Prostate Cancer,” was published in JCO Precision Oncology (DOI 10.1200/PO.23.00230).

Key Points: 
  • The paper, “Circulating and Imaging Biomarkers of Radium-223 Response in Metastatic Castration-Resistant Prostate Cancer,” was published in JCO Precision Oncology (DOI 10.1200/PO.23.00230 ).
  • “Radium-223 is a valuable treatment option for patients with mCRPC, but better biomarkers are needed to identify patients most likely to benefit from therapy.
  • Additionally, imaging assessment in patients with bone-predominant disease has also been limited in patients receiving radium-223.
  • Upon controlling for known prognostic markers, PSA and tAP, the presence of baseline CTC AR-V7 expression was most predictive of OS among patients receiving radium-223.

Latest Wirehouse Breakaway Brings $700 Million in Client Assets to Sanctuary Wealth

Retrieved on: 
Dienstag, April 2, 2024
CEPA, JJ, Growth, History, Marshall College, CRPC, Franklin & Marshall College, Language, CPWA

INDIANAPOLIS, April 2, 2024 /PRNewswire/ -- Sanctuary Wealth (Sanctuary), home to the next generation of elite advisors, welcomes Vincita Investment Partners (Vincita), a Greensboro, North Carolina-based firm with $700 million in client assets. Its founders and managing partners JJ Marus, CEPA, CPWA, CRPC, and Lauren Norris, CFP®, CPFA, are the latest successful advisors to break away from a wirehouse to launch a firm on Sanctuary's Partnered Independence platform.

Key Points: 
  • INDIANAPOLIS, April 2, 2024 /PRNewswire/ -- Sanctuary Wealth (Sanctuary), home to the next generation of elite advisors, welcomes Vincita Investment Partners (Vincita), a Greensboro, North Carolina-based firm with $700 million in client assets.
  • Given their all-encompassing drive to succeed, it is hardly surprising that they've built a highly sophisticated, $700 million practice in just 15 years.
  • Adam Malamed, CEO of Sanctuary Wealth, concluded, "Sanctuary is uniquely positioned to help breakaway teams seamlessly transition to independence and grow their businesses on their terms.
  • Sanctuary is committed to helping them deepen client relationships and accelerate their growth."

Latitude Wealth Advisors Selects Osaic for Growth Platform and Client Services

Retrieved on: 
Montag, März 11, 2024
Culture, Organization, Growth, Partnership, Ameriprise Financial, Acquisition, Business development, CRPC, MSFS, CLU, RICP, CFP, Marketing, Family, CLTC, Chfc, Financial adviser

PHOENIX, March 11, 2024 /PRNewswire/ -- Osaic, one of the nation's largest providers of wealth management services, announced the addition of Latitude Wealth Advisors ("Latitude"), a wealth management firm located in Hauppauge, New York. Latitude serves hundreds of families and businesses, representing $210 million in total client assets. The firm was formerly affiliated with Ameriprise Financial and joins Osaic through Affiliated Advisors, one of Osaic's largest enterprise OSJs.

Key Points: 
  • Former Ameriprise Firm with $210 million in Client Assets Joins Affiliated Advisors, One of Osaic's Largest Enterprise OSJs
    PHOENIX, March 11, 2024 /PRNewswire/ -- Osaic, one of the nation's largest providers of wealth management services, announced the addition of Latitude Wealth Advisors ("Latitude"), a wealth management firm located in Hauppauge, New York.
  • The firm was formerly affiliated with Ameriprise Financial and joins Osaic through Affiliated Advisors, one of Osaic's largest enterprise OSJs.
  • With the addition of Latitude Wealth Advisors, Affiliated Advisors now serves over 100 advisors and 60 staff, representing more than $4 billion in client assets.
  • We welcome Latitude to the family and congratulate Rita and her team at Affiliated Advisors for their ongoing success in attracting top-tier advisors and practices to the Osaic platform."

Summary of opinion: Xtandi, 21/03/2024 Positive

Retrieved on: 
Mittwoch, April 3, 2024
Civil service commission, Prostate cancer, Disease, BCR, Committee, CRPC, Medication package insert, European Commission, Marketing, CHMP, Birth control

The CHMP adopted a new indication for the treatment of adult men with high-risk biochemical recurrent (BCR) non-metastatic hormone-sensitive prostate cancer.

Key Points: 
  • The CHMP adopted a new indication for the treatment of adult men with high-risk biochemical recurrent (BCR) non-metastatic hormone-sensitive prostate cancer.
  • - in combination with androgen deprivation therapy for the treatment of adult men with metastatic hormone-sensitive prostate cancer (mHSPC) (see section 5.1).
  • - for the treatment of adult men with high-risk non-metastatic castration-resistant prostate cancer (CRPC) (see section 5.1).
  • - for the treatment of adult men with metastatic CRPC whose disease has progressed on or after docetaxel therapy.

Summary of opinion: Xtandi, 21/03/2024 Positive

Retrieved on: 
Mittwoch, April 3, 2024
Civil service commission, Prostate cancer, Disease, BCR, Committee, CRPC, Medication package insert, European Commission, Marketing, CHMP, Birth control

The CHMP adopted a new indication for the treatment of adult men with high-risk biochemical recurrent (BCR) non-metastatic hormone-sensitive prostate cancer.

Key Points: 
  • The CHMP adopted a new indication for the treatment of adult men with high-risk biochemical recurrent (BCR) non-metastatic hormone-sensitive prostate cancer.
  • - in combination with androgen deprivation therapy for the treatment of adult men with metastatic hormone-sensitive prostate cancer (mHSPC) (see section 5.1).
  • - for the treatment of adult men with high-risk non-metastatic castration-resistant prostate cancer (CRPC) (see section 5.1).
  • - for the treatment of adult men with metastatic CRPC whose disease has progressed on or after docetaxel therapy.

Summary of opinion: Xtandi, 21/03/2024 Positive

Retrieved on: 
Mittwoch, April 3, 2024
Civil service commission, Prostate cancer, Disease, BCR, Committee, CRPC, Medication package insert, European Commission, Marketing, CHMP, Birth control

The CHMP adopted a new indication for the treatment of adult men with high-risk biochemical recurrent (BCR) non-metastatic hormone-sensitive prostate cancer.

Key Points: 
  • The CHMP adopted a new indication for the treatment of adult men with high-risk biochemical recurrent (BCR) non-metastatic hormone-sensitive prostate cancer.
  • - in combination with androgen deprivation therapy for the treatment of adult men with metastatic hormone-sensitive prostate cancer (mHSPC) (see section 5.1).
  • - for the treatment of adult men with high-risk non-metastatic castration-resistant prostate cancer (CRPC) (see section 5.1).
  • - for the treatment of adult men with metastatic CRPC whose disease has progressed on or after docetaxel therapy.

Merus Announces Financial Results for the Fourth Quarter and Full Year 2023 and Provides Business Update

Retrieved on: 
Mittwoch, Februar 28, 2024
Cetuximab, Research, Castration, PRS, Intellectual property, Patient, Pancreatic cancer, HNSCC, EAP, Eli Lilly and Company, CRPC, Drug design, BLA, FTD, HER2, MET, Congress, Afatinib, Partnership, NSCLC, CD3, EGFR, ESMO, BTD, Betta, CRC, AACR, Safety, Biomarker, RECIST, Clinical trial, Oncology, Prostate cancer, Neoplasm, FDA, Pembrolizumab, Lung, Disease, Travel, Pharmaceutical industry

Merus also continues to evaluate patients with untreated advanced PD-L1+ HNSCC treated with petosemtamab 1500 mg in combination with pembrolizumab.

Key Points: 
  • Merus also continues to evaluate patients with untreated advanced PD-L1+ HNSCC treated with petosemtamab 1500 mg in combination with pembrolizumab.
  • Merus plans to report initial interim efficacy and safety data from this cohort in the second quarter of 2024.
  • Merus achieved a milestone and received a payment of $2.5 million related to the advancement of this program in the third quarter of 2023.
  • Merus also achieved an additional milestone of $1 million for candidate nomination in the fourth quarter of 2023.

LPL Financial Welcomes Bice Wealth Management

Retrieved on: 
Mittwoch, Februar 21, 2024
SAN, Office, Freedom, AAMS, RIA, CRPC, Business development, Bice, LPL, Financial adviser

SAN DIEGO, Feb. 21, 2024 (GLOBE NEWSWIRE) -- LPL Financial LLC (Nasdaq:LPLA) announced today that financial advisor Cubby Bice MBA, AAMS, CRPC has joined LPL Financial’s broker-dealer, RIA and custodial platforms.

Key Points: 
  • SAN DIEGO, Feb. 21, 2024 (GLOBE NEWSWIRE) -- LPL Financial LLC (Nasdaq:LPLA) announced today that financial advisor Cubby Bice MBA, AAMS, CRPC has joined LPL Financial’s broker-dealer, RIA and custodial platforms.
  • He reported serving approximately $130 million in advisory, brokerage and retirement plan assets* and joins LPL from Osaic.
  • Based in Mooresville, N.C., Bice Wealth Management is an independent financial firm committed to helping clients pursue their financial goals.
  • We look forward to a long-lasting relationship with Bice Wealth Management.”

M&K Legacy Wealth Brings $1 Billion in Client Assets to Sanctuary Wealth

Retrieved on: 
Freitag, März 8, 2024
Freedom, Sanctuary, Stifel, Culture, CRPC, Retirement, CFA, APMA, Partner, Financial adviser

INDIANAPOLIS, March 8, 2024 /PRNewswire/ -- Sanctuary Wealth (Sanctuary), home to the next generation of elite advisors, welcomes M&K Legacy Wealth (M&K) the latest breakaway to launch their own firm with Sanctuary's Partnered Independence platform. With $1 billion in total client assets, Indianapolis-based M&K was formerly known as Tanner Wealth Management Group and employed by Stifel.

Key Points: 
  • INDIANAPOLIS, March 8, 2024 /PRNewswire/ -- Sanctuary Wealth (Sanctuary), home to the next generation of elite advisors, welcomes M&K Legacy Wealth (M&K) the latest breakaway to launch their own firm with Sanctuary's Partnered Independence platform.
  • With $1 billion in total client assets, Indianapolis-based M&K was formerly known as Tanner Wealth Management Group and employed by Stifel.
  • Vince Fertitta, President, Sanctuary Wealth said, "Being introduced to great teams like M&K by our existing Partner Firms is the best compliment Sanctuary can receive.
  • Adam Malamed, CEO, Sanctuary Wealth, concluded, "J.,Chad and their entire team are the perfect fit for our business model and culture, and we are thrilled to welcome them to the Sanctuary Wealth family.